Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
Collections
Subject
Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Pyrazoles
Pyridines
Proto-Oncogene Proteins
Protein Kinase Inhibitors
Neoplasm Staging
Treatment Outcome
Protein-Tyrosine Kinases
Genetic Testing
Molecular Targeted Therapy
Biomarkers, Tumor
Crizotinib
Research team
Thoracic Oncology
Language
eng
Date accepted
2016-11-10
License start date
2017-02
Citation
Lung cancer (Amsterdam, Netherlands), 2017, 104 pp. 131 - 133